卡达摩宁通过PI3K-AKT信号通路抑制病的发展
Zhimin Ye1, Zhiyuan Niu2, Juan Li2
1Department of pathology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China; Department of Pathology, Basic Medical School, Central South University, Changsha, Hunan 410013, China; Department of pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Ecotoxicology and environmental safety
|September 22, 2024
概括
卡达摩宁 (CDM) 通过减少肺纤维化和纤维细胞激活,有效地抑制了病的进展. 这项研究揭示了CDM.
科学领域:
- 职业医学 职业医学是专业的.
- 肺纤维化研究研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 病是一种严重的职业肺部疾病,治疗选择有限.
- 纤维化,以炎症和纤维细胞激活为特征,是病的一个关键特征.
- 卡达摩宁 (CDM) 具有已知的抗炎和抗纤维性质.
研究的目的:
- 为了研究卡达蒙因 (CDM) 对病的抗纤维作用.
- 阐明CDM在病中的作用背后的分子机制.
- 评估CDM作为一种潜在的治疗病的药物.
主要方法:
- 建立了一个 (SiO2-M) 刺激的纤维细胞细胞模型.
- 使用了西布洛特 (Western Blot,简称WB),RT-qPCR和免疫光技术进行分子分析.
- 通过内内悬浮注射开发了一种病小鼠模型.
- 执行RNA测序以识别涉及的信号通路.
主要成果:
- 在体外,CDM显著抑制SiO2-M诱导的纤维细胞激活,增殖和迁移.
- 在体内研究表明,CDM在症小鼠模型中减缓了肺纤维化进展.
- RNA测序表明,酸丁醇3-酶/蛋白酶B (PI3K/AKT) 信号通路调解了CDM的抗纤维效应.
结论:
- 卡达摩宁 (CDM) 显示出对抗病的显著抗纤维作用.
- 在症中CDM的治疗潜力与其对PI3K/AKT信号通路的调制有关.
- CDM为开发用于症的新药治疗提供了一个有前途的途径.
更多相关视频
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


